Childhood obesity and GLP-1
Semaglutide for Children: What the First STEP Young Results Really Show
A phase 3 result may open a new clinical possibility without making a medicine an immediate answer for every child. In STEP Young, age, obesity severity, follow-up and the limits of the data matter as much as the headline percentage.
What was announced
On 7 September 2026, Novo Nordisk released the first results from STEP Young, a randomised, double-blind, placebo-controlled trial. The analysed group included 165 children aged 6 to under 12 with obesity. At 68 weeks, semaglutide reduced body mass index more than placebo, with both groups also receiving a reduced-calorie diet and increased physical activity.
Where the 40.4% figure comes from
According to the company, 40.4% of treated children moved below the obesity threshold, compared with none receiving placebo. This figure uses an estimand that assumes treatment adherence. More than 85% began with severe obesity, so the findings do not describe children seeking a small appearance-driven weight change.
What we still do not know
Full results have not yet been presented at a scientific meeting or published in a peer-reviewed journal. Independent assessment of attrition, group differences, adverse events and statistical analyses therefore remains limited. Follow-up for later study outcomes is also continuing.
Safety requires longer observation
The company reported a safety profile consistent with previous studies and no new concerns involving growth or pubertal development. This is encouraging but does not establish long-term safety for every child. Gastrointestinal effects, growth, puberty, mental health, body composition and the child's relationship with food must be considered together.
A trial result is not automatic authorisation
The announcement does not by itself change the approved indication in Brazil or make Ozempic, Wegovy or any semaglutide product available for children under 12. Paediatric use depends on regulatory review, an authorised presentation, diagnosis and specialist medical follow-up.
Where nutrition fits
Nutrition care should not become a punitive diet. It supports growth, adequate energy and nutrients, tolerable meals, lean mass, family routines and lower stigma. Severe childhood obesity may require coordinated paediatric, endocrinology, nutrition, activity and mental-health care.
Personalized care
A plan should fit the person, not the trend.
Scientific references
This page is educational and does not replace individual medical or nutrition assessment.